$LLY
ELI LILLY & Co

2012 Form 10-K Financial Statement

#000005947813000007 Filed on February 21, 2013

View on sec.gov

Income Statement

Concept 2012 2011 Q4 2011
Revenue $22.60B $6.047B $24.29B
YoY Change -6.93% -2.27% 5.25%
Cost Of Revenue $4.797B $1.322B $5.068B
YoY Change -5.36% 7.26% 16.07%
Gross Profit $17.81B $4.725B $19.22B
YoY Change -7.35% -4.64% 2.72%
Gross Profit Margin 78.78% 78.14% 79.13%
Selling, General & Admin $7.514B $2.133B $7.880B
YoY Change -4.65% 7.28% 11.72%
% of Gross Profit 42.19% 45.15% 41.0%
Research & Development $5.278B $1.355B $5.021B
YoY Change 5.12% -5.76% 2.8%
% of Gross Profit 29.64% 28.68% 26.12%
Depreciation & Amortization $1.462B $318.9M $1.374B
YoY Change 6.45% -5.79% 3.42%
% of Gross Profit 8.21% 6.75% 7.15%
Operating Expenses $12.79B $3.489B $12.90B
YoY Change -0.85% 1.81% 8.07%
Operating Profit $5.015B $1.236B $6.318B
YoY Change -20.62% -19.1% -6.71%
Interest Expense $177.8M -$25.70M $186.0M
YoY Change -4.41% -11.99% 0.27%
% of Operating Profit 3.55% -2.08% 2.94%
Other Income/Expense, Net $674.0M -$1.100M -$179.0M
YoY Change -476.54% -89.22% 3480.0%
Pretax Income $4.902B $1.042B $6.139B
YoY Change -20.16% -26.09% -9.28%
Income Tax $1.320B $183.6M $1.002B
% Of Pretax Income 26.92% 17.62% 16.32%
Net Earnings $4.089B $858.2M $4.348B
YoY Change -5.96% -26.62% -14.24%
Net Earnings / Revenue 18.09% 14.19% 17.9%
Basic Earnings Per Share $3.67 $3.90
Diluted Earnings Per Share $3.66 $769.1K $3.90
COMMON SHARES
Basic Shares Outstanding 1.113B shares 1.114B shares
Diluted Shares Outstanding 1.117B shares 1.114B shares

Balance Sheet

Concept 2012 2011 Q4 2011
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.684B $6.897B $6.897B
YoY Change -17.59% 2.53% 2.53%
Cash & Equivalents $4.019B $5.923B $5.923B
Short-Term Investments $1.666B $975.0M $975.0M
Other Short-Term Assets $822.0M $813.0M $813.0M
YoY Change 1.11% -43.42% -43.42%
Inventory $2.644B $2.300B $2.300B
Prepaid Expenses $813.4M
Receivables $3.336B $3.598B $3.598B
Other Receivables $552.0M $640.0M $640.0M
Total Short-Term Assets $13.04B $14.25B $14.25B
YoY Change -8.49% -3.99% -3.99%
LONG-TERM ASSETS
Property, Plant & Equipment $7.760B $7.760B $7.760B
YoY Change 0.0% -2.28% -2.28%
Goodwill $1.435B
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.313B $4.030B $4.030B
YoY Change 56.65% 126.4% 126.4%
Other Assets $2.534B $2.493B $2.493B
YoY Change 1.64% 53.72% 53.7%
Total Long-Term Assets $21.36B $11.65B $19.41B
YoY Change 10.04% -27.9% 20.12%
TOTAL ASSETS
Total Short-Term Assets $13.04B $14.25B $14.25B
Total Long-Term Assets $21.36B $11.65B $19.41B
Total Assets $34.40B $33.66B $33.66B
YoY Change 2.2% 8.58% 8.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.188B $1.125B $1.125B
YoY Change 5.6% 4.96% 4.94%
Accrued Expenses $940.0M $805.0M $805.0M
YoY Change 16.77% -5.52% -5.52%
Deferred Revenue
YoY Change
Short-Term Debt $12.00M $1.522B $1.522B
YoY Change -99.21% 875.83% 875.64%
Long-Term Debt Due $1.517B
YoY Change
Total Short-Term Liabilities $8.390B $8.931B $8.931B
YoY Change -6.06% 28.93% 28.93%
LONG-TERM LIABILITIES
Long-Term Debt $5.519B $5.465B $5.465B
YoY Change 0.99% -19.29% -19.29%
Other Long-Term Liabilities $5.716B $1.574B $5.729B
YoY Change -0.23% -67.82% 17.13%
Total Long-Term Liabilities $11.24B $11.19B $11.19B
YoY Change 0.37% -4.02% -4.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.390B $8.931B $8.931B
Total Long-Term Liabilities $11.24B $11.19B $11.19B
Total Liabilities $19.63B $20.12B $20.12B
YoY Change -2.41% 8.31% 8.27%
SHAREHOLDERS EQUITY
Retained Earnings $14.90B
YoY Change
Common Stock $5.611B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $95.30M
YoY Change
Treasury Stock Shares 853.0K shares
Shareholders Equity $14.77B $13.54B $13.54B
YoY Change
Total Liabilities & Shareholders Equity $34.40B $33.66B $33.66B
YoY Change 2.2% 8.58% 8.58%

Cashflow Statement

Concept 2012 2011 Q4 2011
OPERATING ACTIVITIES
Net Income $4.089B $858.2M $4.348B
YoY Change -5.96% -26.62% -14.24%
Depreciation, Depletion And Amortization $1.462B $318.9M $1.374B
YoY Change 6.45% -5.79% 3.42%
Cash From Operating Activities $5.305B $1.945B $7.235B
YoY Change -26.67% -12.72% 5.51%
INVESTING ACTIVITIES
Capital Expenditures -$1.044B -$283.1M -$1.693B
YoY Change -38.32% 3.21% 42.66%
Acquisitions $199.3M $307.8M
YoY Change -35.25% -49.49%
Other Investing Activities -$64.40M -$1.594B $112.2M
YoY Change -157.4% 23.52% -48.84%
Cash From Investing Activities -$2.833B -$1.877B -$4.824B
YoY Change -41.28% 19.96% 52.68%
FINANCING ACTIVITIES
Cash Dividend Paid $2.187B $2.180B
YoY Change 0.33% 0.68%
Common Stock Issuance & Retirement, Net $721.1M $0.00
YoY Change
Debt Paid & Issued, Net $1.511B $61.70M
YoY Change 2349.11% 5509.09%
Cash From Financing Activities -$4.420B -650.9M -$2.370B
YoY Change 86.49% 18.43% 17.21%
NET CHANGE
Cash From Operating Activities $5.305B 1.945B $7.235B
Cash From Investing Activities -$2.833B -1.877B -$4.824B
Cash From Financing Activities -$4.420B -650.9M -$2.370B
Net Change In Cash -$1.948B -583.0M $40.20M
YoY Change -4944.78% -611.4% -97.6%
FREE CASH FLOW
Cash From Operating Activities $5.305B $1.945B $7.235B
Capital Expenditures -$1.044B -$283.1M -$1.693B
Free Cash Flow $6.349B $2.228B $8.927B
YoY Change -28.88% -10.97% 10.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
552000000 USD
CY2011Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
640200000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1188300000 USD
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1125200000 USD
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3597700000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3336300000 USD
CY2011Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
1086300000 USD
CY2012Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
1334300000 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7157800000 USD
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6833800000 USD
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3797100000 USD
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3858600000 USD
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4963100000 USD
CY2011Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4886800000 USD
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
141500000 USD
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
231000000 USD
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
147400000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
108500000 USD
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
110100000 USD
CY2010 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
385700000 USD
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
469000000 USD
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
563000000 USD
CY2012 us-gaap Asset Impairment Charges
AssetImpairmentCharges
206600000 USD
CY2011 us-gaap Asset Impairment Charges
AssetImpairmentCharges
149600000 USD
CY2010 us-gaap Asset Impairment Charges
AssetImpairmentCharges
50000000 USD
CY2012Q4 us-gaap Assets
Assets
34398900000 USD
CY2011Q4 us-gaap Assets
Assets
33659800000 USD
CY2011Q4 us-gaap Assets Current
AssetsCurrent
14248200000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
13038700000 USD
CY2012Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
13600000000 USD
CY2011Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
11651300000 USD
CY2011Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
2164400000 USD
CY2012Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
2102000000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
373900000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
4776500000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
754000000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1665500000 USD
CY2012Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
7569900000 USD
CY2011 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
140000000 USD
CY2012 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
82300000 USD
CY2010 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
110700000 USD
CY2011 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
9900000 USD
CY2010 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
4800000 USD
CY2012 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
10900000 USD
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
29000000 USD
CY2011Q4 us-gaap Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
80000000 USD
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
140500000 USD
CY2011Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
103000000 USD
CY2012 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Other Percentage Of Nonperforming Assets
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureOtherPercentageOfNonperformingAssets
0.90
CY2012 us-gaap Average Remaining Maturity Of Foreign Currency Derivatives1
AverageRemainingMaturityOfForeignCurrencyDerivatives1
P12M
CY2011Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
6135700000 USD
CY2012Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
6373800000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5922500000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4018800000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4462900000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5993200000 USD
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1530300000 USD
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-70700000 USD
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1903700000 USD
CY2011Q4 us-gaap Common Stock Shares Held In Employee Trust
CommonStockSharesHeldInEmployeeTrust
3013100000 USD
CY2012Q4 us-gaap Common Stock Shares Held In Employee Trust
CommonStockSharesHeldInEmployeeTrust
3013200000 USD
CY2011Q4 us-gaap Common Stock Shares Held In Employee Trust Shares
CommonStockSharesHeldInEmployeeTrustShares
50000000 shares
CY2012Q4 us-gaap Common Stock Shares Held In Employee Trust Shares
CommonStockSharesHeldInEmployeeTrustShares
50000000 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1146493000 shares
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1158644000 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
716600000 USD
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
724100000 USD
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4150100000 USD
CY2010 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4871300000 USD
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3159200000 USD
CY2011Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1036000000 USD
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
799900000 USD
CY2012 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4796500000 USD
CY2011 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5067900000 USD
CY2010 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4366200000 USD
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
596800000 USD
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
671400000 USD
CY2010 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
376200000 USD
CY2011 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
759500000 USD
CY2010 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
513900000 USD
CY2012 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
540600000 USD
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1193600000 USD
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1408000000 USD
CY2010 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
913400000 USD
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
56200000 USD
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-22900000 USD
CY2010 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23300000 USD
CY2011Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0300
CY2012Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0320
CY2010 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
624400000 USD
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
87000000 USD
CY2011 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-398500000 USD
CY2010 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-55200000 USD
CY2011 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-34700000 USD
CY2012 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
29900000 USD
CY2010 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
542300000 USD
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
126000000 USD
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-406200000 USD
CY2011 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
27000000 USD
CY2010 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-26900000 USD
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
9100000 USD
CY2011Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
207100000 USD
CY2012Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
278600000 USD
CY2012Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
366800000 USD
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4006800000 USD
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3821400000 USD
CY2012Q4 us-gaap Deferred Tax Assets Hedging Transactions
DeferredTaxAssetsHedgingTransactions
232800000 USD
CY2011Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
277200000 USD
CY2012Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
159600000 USD
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
278900000 USD
CY2011Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
520000000 USD
CY2011Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3394900000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3145600000 USD
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
406100000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
370100000 USD
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
100700000 USD
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
361500000 USD
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
292800000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
16400000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1081800000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
1286500000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
94500000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
113200000 USD
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
146200000 USD
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances
153800000 USD
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
675800000 USD
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
611900000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2874900000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2866700000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
1048000000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
422300000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
489200000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
573400000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
257000000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
708800000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
797600000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Interests In Financial Assets Continued To Be Held
DeferredTaxLiabilitiesInterestsInFinancialAssetsContinuedToBeHeld
196900000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
451000000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
407100000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Undistributed Foreign Earnings
DeferredTaxLiabilitiesUndistributedForeignEarnings
920400000 USD
CY2011Q4 us-gaap Deferred Tax Liabilities Undistributed Foreign Earnings
DeferredTaxLiabilitiesUndistributedForeignEarnings
940200000 USD
CY2012Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
9460000000 USD
CY2011Q4 us-gaap Defined Benefit Plan Accumulated Benefit Obligation
DefinedBenefitPlanAccumulatedBenefitObligation
8200000000 USD
CY2012 us-gaap Defined Benefit Plan Effect Of One Percentage Point Decrease On Accumulated Postretirement Benefit Obligation1
DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1
193600000 USD
CY2012 us-gaap Defined Benefit Plan Effect Of One Percentage Point Decrease On Service And Interest Cost Components1
DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1
12600000 USD
CY2012 us-gaap Defined Benefit Plan Effect Of One Percentage Point Increase On Accumulated Postretirement Benefit Obligation
DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation
218200000 USD
CY2012 us-gaap Defined Benefit Plan Effect Of One Percentage Point Increase On Service And Interest Cost Components
DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents
15600000 USD
CY2012Q4 us-gaap Defined Benefit Plan Estimated Future Employer Contributions In Next Fiscal Year
DefinedBenefitPlanEstimatedFutureEmployerContributionsInNextFiscalYear
60000000 USD
CY2011Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
1339000000 USD
CY2012Q4 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
1518000000 USD
CY2012 us-gaap Defined Benefit Plan Health Care Cost Trend Rate Assumed For Next Fiscal Year
DefinedBenefitPlanHealthCareCostTrendRateAssumedForNextFiscalYear
0.071
CY2012Q4 us-gaap Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation
DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
8020000000 USD
CY2011Q4 us-gaap Defined Benefit Plan Pension Plans With Accumulated Benefit Obligations In Excess Of Plan Assets Aggregate Accumulated Benefit Obligation
DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
7030000000 USD
CY2011Q4 us-gaap Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Benefit Obligation
DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateBenefitObligation
8120000000 USD
CY2012Q4 us-gaap Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Benefit Obligation
DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateBenefitObligation
9150000000 USD
CY2011Q4 us-gaap Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets
DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
5750000000 USD
CY2012Q4 us-gaap Defined Benefit Plan Plans With Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets
DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
6580000000 USD
CY2012 us-gaap Defined Benefit Plan Ultimate Health Care Cost Trend Rate
DefinedBenefitPlanUltimateHealthCareCostTrendRate
0.050
CY2010 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
119800000 USD
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
127300000 USD
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
117600000 USD
CY2010 us-gaap Depreciation
Depreciation
749100000 USD
CY2011 us-gaap Depreciation
Depreciation
732400000 USD
CY2012 us-gaap Depreciation
Depreciation
754000000 USD
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1373600000 USD
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1328200000 USD
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1462200000 USD
CY2011 us-gaap Derivative Instruments Gain Loss Recognized In Income Net
DerivativeInstrumentsGainLossRecognizedInIncomeNet
-35800000 USD
CY2009 us-gaap Derivative Instruments Gain Loss Recognized In Income Net
DerivativeInstrumentsGainLossRecognizedInIncomeNet
12000000 USD
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-28100000 USD
CY2010 us-gaap Derivative Instruments Gain Loss Recognized In Income Net
DerivativeInstrumentsGainLossRecognizedInIncomeNet
97400000 USD
CY2011 us-gaap Derivative Instruments Loss Reclassified From Accumulated Oci Into Income Effective Portion
DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
9000000 USD
CY2009 us-gaap Derivative Instruments Loss Reclassified From Accumulated Oci Into Income Effective Portion
DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
9000000 USD
CY2010 us-gaap Derivative Instruments Loss Reclassified From Accumulated Oci Into Income Effective Portion
DerivativeInstrumentsLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortion
9000000 USD
CY2011Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
542300000 USD
CY2012Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
541400000 USD
CY2010 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.58
CY2011 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.90
CY2012 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.67
CY2011 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.90
CY2010 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.58
CY2012 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.66
CY2011 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-110900000 USD
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
43900000 USD
CY2010 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-144800000 USD
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
804700000 USD
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
940300000 USD
CY2012 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P20M
CY2011 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
51600000 USD
CY2010 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
80800000 USD
CY2012 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
49500000 USD
CY2012 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y0M0D
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
540000000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
200000000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
380000000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
480000000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
530000000 USD
CY2010 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 USD
CY2011 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
0 USD
CY2012 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
787800000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
1501300000 USD
CY2011Q4 us-gaap Goodwill
Goodwill
1434700000 USD
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2011 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
151500000 USD
CY2012 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
205000000 USD
CY2010 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0 USD
CY2012 us-gaap Impairment Of Investments
ImpairmentOfInvestments
12200000 USD
CY2010 us-gaap Impairment Of Investments
ImpairmentOfInvestments
12000000 USD
CY2011 us-gaap Impairment Of Investments
ImpairmentOfInvestments
26800000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6138900000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4901500000 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6767200000 USD
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5408200000 USD
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
5349500000 USD
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
6525200000 USD
CY2011Q4 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
300000000 USD
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1319600000 USD
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1001800000 USD
CY2010 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1455700000 USD
CY2012 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
593800000 USD
CY2010 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
823300000 USD
CY2011 us-gaap Income Tax Reconciliation Deductions Extraterritorial Income Exclusion
IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion
796700000 USD
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1892900000 USD
CY2011 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
1872300000 USD
CY2010 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
2283800000 USD
CY2010 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-6700000 USD
CY2011 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
29400000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
203900000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9000000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
83200000 USD
CY2011 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
80800000 USD
CY2012 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
11200000 USD
CY2012 us-gaap Income Tax Reconciliation Tax Settlements Domestic
IncomeTaxReconciliationTaxSettlementsDomestic
0 USD
CY2011 us-gaap Income Tax Reconciliation Tax Settlements Domestic
IncomeTaxReconciliationTaxSettlementsDomestic
-85300000 USD
CY2010 us-gaap Income Tax Reconciliation Tax Settlements Domestic
IncomeTaxReconciliationTaxSettlementsDomestic
0 USD
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
992000000 USD
CY2011 us-gaap Income Taxes Paid
IncomeTaxesPaid
943000000 USD
CY2010 us-gaap Income Taxes Paid
IncomeTaxesPaid
861000000 USD
CY2011 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
188800000 USD
CY2012 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-361800000 USD
CY2010 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
319100000 USD
CY2010 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-363900000 USD
CY2011 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
591400000 USD
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-336100000 USD
CY2012 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-126000000 USD
CY2011 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
268500000 USD
CY2010 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-559700000 USD
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-203100000 USD
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
307900000 USD
CY2010 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-157000000 USD
CY2011 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-642700000 USD
CY2012 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-231000000 USD
CY2010 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-340500000 USD
CY2010 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
26000000 USD
CY2012 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
21000000 USD
CY2011 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
25700000 USD
CY2010 us-gaap Interest Expense
InterestExpense
185500000 USD
CY2011 us-gaap Interest Expense
InterestExpense
186000000 USD
CY2012 us-gaap Interest Expense
InterestExpense
177800000 USD
CY2011 us-gaap Interest Paid Net
InterestPaidNet
167400000 USD
CY2012 us-gaap Interest Paid Net
InterestPaidNet
171900000 USD
CY2010 us-gaap Interest Paid Net
InterestPaidNet
176300000 USD
CY2012Q4 us-gaap Interest Rate Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months Net
InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet
9000000 USD
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
786400000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
834400000 USD
CY2012Q4 us-gaap Inventory Gross
InventoryGross
2826300000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1010000000 USD
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5464700000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5519400000 USD
CY2012Q4 us-gaap Long Term Debt Percentage Bearing Fixed Interest Rate
LongTermDebtPercentageBearingFixedInterestRate
1.00
CY2011Q4 us-gaap Long Term Investments
LongTermInvestments
4029800000 USD
CY2011Q4 us-gaap Inventory Gross
InventoryGross
2510400000 USD
CY2011Q4 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
210600000 USD
CY2012Q4 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
182500000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
2643800000 USD
CY2011Q4 us-gaap Inventory Net
InventoryNet
2299800000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
256100000 USD
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
205800000 USD
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1518200000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1735800000 USD
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
79900000 USD
CY2010 us-gaap Investment Income Interest
InvestmentIncomeInterest
51900000 USD
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
105000000 USD
CY2011Q4 us-gaap Land
Land
202500000 USD
CY2012Q4 us-gaap Land
Land
201400000 USD
CY2010 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
255700000 USD
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
267400000 USD
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
285800000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34398900000 USD
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33659800000 USD
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8930900000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8389500000 USD
CY2012Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11235500000 USD
CY2011Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11193300000 USD
CY2012Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
0 USD
CY2012Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
1360000000 USD
CY2011Q4 us-gaap Long Term Debt
LongTermDebt
6981500000 USD
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
5531300000 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11900000 USD
CY2011Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1516800000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11900000 USD
CY2012Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
1000000000 USD
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6856800000 USD
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7234500000 USD
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5304800000 USD
CY2011Q4 us-gaap Minority Interest
MinorityInterest
-6100000 USD
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4419600000 USD
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2369900000 USD
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2021900000 USD
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3159800000 USD
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2832800000 USD
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4824400000 USD
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
6313300000 USD
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
7542900000 USD
CY2011Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
7219900000 USD
CY2012 us-gaap Maximum Remaining Maturity Of Foreign Currency Derivatives1
MaximumRemainingMaturityOfForeignCurrencyDerivatives1
P45D
CY2012Q4 us-gaap Minority Interest
MinorityInterest
8700000 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
5069500000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
4088600000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
4347700000 USD
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4088600000 USD
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4347700000 USD
CY2010 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5069500000 USD
CY2012 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
170700000 USD
CY2011 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
178000000 USD
CY2010Q4 us-gaap Noncurrent Assets
NoncurrentAssets
9274200000 USD
CY2011Q4 us-gaap Noncurrent Assets
NoncurrentAssets
9372400000 USD
CY2012Q4 us-gaap Noncurrent Assets
NoncurrentAssets
8990500000 USD
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
674000000 USD
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-179000000 USD
CY2010 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000000 USD
CY2011Q4 us-gaap Notes Payable
NotesPayable
6387400000 USD
CY2012Q4 us-gaap Notes Payable
NotesPayable
4887300000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2534000000 USD
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2493400000 USD
CY2012 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
34400000 USD
CY2010 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
60400000 USD
CY2011 us-gaap Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Tax
OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
-383800000 USD
CY2010 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
-325100000 USD
CY2012 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
160900000 USD
CY2011 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
-244800000 USD
CY2012 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
88500000 USD
CY2011 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-178500000 USD
CY2010 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
80800000 USD
CY2010 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-122000000 USD
CY2011 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1618700000 USD
CY2012 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
129500000 USD
CY2012 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
8700000 USD
CY2010 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
-26600000 USD
CY2011 us-gaap Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax
OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax
44800000 USD
CY2010 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-198200000 USD
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1188500000 USD
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
61500000 USD
CY2012 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
128600000 USD
CY2010 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
-148900000 USD
CY2011 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
1240200000 USD
CY2012 us-gaap Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
-46400000 USD
CY2011 us-gaap Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
-54700000 USD
CY2010 us-gaap Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax
-27600000 USD
CY2012 us-gaap Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax
5900000 USD
CY2010 us-gaap Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax
-5800000 USD
CY2011 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-430200000 USD
CY2012 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
68000000 USD
CY2011 us-gaap Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax
-5800000 USD
CY2010 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
76200000 USD
CY2012 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
USD
CY2010 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
-9300000 USD
CY2011 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
32600000 USD
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
30800000 USD
CY2011 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-64400000 USD
CY2010 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
27300000 USD
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2481200000 USD
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2738900000 USD
CY2012Q4 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
0 USD
CY2011Q4 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
121600000 USD
CY2012Q2 us-gaap Other Liabilities Fair Value Disclosure
OtherLiabilitiesFairValueDisclosure
50000000 USD
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1573800000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1369400000 USD
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000000 USD
CY2010 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
128600000 USD
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-72900000 USD
CY2012Q4 us-gaap Other Notes Payable
OtherNotesPayable
37400000 USD
CY2011Q4 us-gaap Other Notes Payable
OtherNotesPayable
37600000 USD
CY2010 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-178600000 USD
CY2012 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
120500000 USD
CY2011 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-17800000 USD
CY2011 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
681700000 USD
CY2010 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
633800000 USD
CY2012 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
633000000 USD
CY2011 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
112200000 USD
CY2010 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
219300000 USD
CY2012 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
100600000 USD
CY2010 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
686500000 USD
CY2012 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
-375100000 USD
CY2011 us-gaap Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
250900000 USD
CY2010 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2012 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
721100000 USD
CY2011 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2010 us-gaap Payments Of Dividends
PaymentsOfDividends
2165300000 USD
CY2012 us-gaap Payments Of Dividends
PaymentsOfDividends
2187400000 USD
CY2011 us-gaap Payments Of Dividends
PaymentsOfDividends
2180100000 USD
CY2010 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
609400000 USD
CY2011 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
307800000 USD
CY2012 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
199300000 USD
CY2011 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
632900000 USD
CY2012 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
138800000 USD
CY2010 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
442400000 USD
CY2011 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
4459400000 USD
CY2012 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
7618600000 USD
CY2010 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
1067200000 USD
CY2011 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
672000000 USD
CY2012 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
905400000 USD
CY2010 us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
694300000 USD
CY2012Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
3012400000 USD
CY2011Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
3068500000 USD
CY2012Q4 us-gaap Percentage Of Lifo Inventory
PercentageOfLIFOInventory
0.40
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
822300000 USD
CY2011Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
813400000 USD
CY2012 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
165000000 USD
CY2011 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
-165000000 USD
CY2010 us-gaap Proceeds From Payments For Long Term Loans For Related Parties
ProceedsFromPaymentsForLongTermLoansForRelatedParties
0 USD
CY2011 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
6000000 USD
CY2012 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2010 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
19400000 USD
CY2012 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-10500000 USD
CY2010 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
125100000 USD
CY2011 us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-141200000 USD
CY2012 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
4355700000 USD
CY2011 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
2138500000 USD
CY2010 us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
584700000 USD
CY2012 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
6529800000 USD
CY2010 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
760300000 USD
CY2011 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
2268300000 USD
CY2010 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 USD
CY2011 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 USD
CY2012 us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
1212100000 USD
CY2012 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
22000000 USD
CY2011 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
25300000 USD
CY2010 us-gaap Proceeds From Sale Of Other Property Plant And Equipment
ProceedsFromSaleOfOtherPropertyPlantAndEquipment
24600000 USD
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14918000000 USD
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14594100000 USD
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7760300000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7760200000 USD
CY2010 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1100000 USD
CY2012 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1500600000 USD
CY2011 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
54600000 USD
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4884200000 USD
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5278100000 USD
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5020800000 USD
CY2011 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
401400000 USD
CY2012 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
281100000 USD
CY2010 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
192000000 USD
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
14897800000 USD
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
16088200000 USD
CY2012 us-gaap Revenues
Revenues
22603400000 USD
CY2010 us-gaap Revenues
Revenues
23076000000 USD
CY2011 us-gaap Revenues
Revenues
24286500000 USD
CY2011 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
23604800000 USD
CY2012 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
21970400000 USD
CY2010 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
22442200000 USD
CY2012 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7513500000 USD
CY2011 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7879900000 USD
CY2010 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7053400000 USD
CY2010 us-gaap Severance Costs
SeveranceCosts
142000000 USD
CY2012 us-gaap Severance Costs
SeveranceCosts
74500000 USD
CY2011 us-gaap Severance Costs
SeveranceCosts
251800000 USD
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
141500000 USD
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
231000000 USD
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
147400000 USD
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
39.65
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
4.50
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
4.50
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
4.90
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.2564
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.2869
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.2910
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.2800
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.2240
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.2761
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0136
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0036
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0136
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0010
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0020
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0010
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
92000000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
3900000 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1600000 shares
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
3800000 shares
CY2010Q3 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
125000000 USD
CY2011Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
5500000 USD
CY2012Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
0 USD
CY2012Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
11900000 USD
CY2011Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
1522300000 USD
CY2011Q4 us-gaap Short Term Investments
ShortTermInvestments
974600000 USD
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
1665500000 USD
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2012 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
16918000 shares
CY2012 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
819200000 USD
CY2011Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13535600000 USD
CY2012Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
14773900000 USD
CY2011 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
85300000 USD
CY2012Q4 us-gaap Tax Credit Carryforward Deferred Tax Asset
TaxCreditCarryforwardDeferredTaxAsset
703200000 USD
CY2011Q4 us-gaap Tax Credit Carryforward Deferred Tax Asset
TaxCreditCarryforwardDeferredTaxAsset
695300000 USD
CY2011Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
261600000 USD
CY2012Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
143500000 USD
CY2011Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
853000 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
2850000 shares
CY2011Q4 us-gaap Treasury Stock Value
TreasuryStockValue
95300000 USD
CY2012Q4 us-gaap Treasury Stock Value
TreasuryStockValue
192400000 USD
CY2012Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
20980000000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1274800000 USD
CY2010Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1619600000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1433800000 USD
CY2009Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1351200000 USD
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
38500000 USD
CY2011 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
492300000 USD
CY2010 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
30200000 USD
CY2010 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
-100000 USD
CY2012 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
-9200000 USD
CY2011 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
-326300000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
187500000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
134600000 USD
CY2010 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
38300000 USD
CY2011 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-47300000 USD
CY2012 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
42300000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
141500000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
186200000 USD
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
89400000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation
UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
2500000 USD
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation
UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
-3000000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Foreign Currency Translation
UnrecognizedTaxBenefitsIncreasesResultingFromForeignCurrencyTranslation
-300000 USD
CY2012 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
70100000 USD
CY2010 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
117000000 USD
CY2011 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
390000000 USD
CY2011 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
-2600000 USD
CY2012 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
-4600000 USD
CY2010 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
-7000000 USD
CY2011Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
812300000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
928100000 USD
CY2010 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1105788000 shares
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1113178000 shares
CY2011 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1113923000 shares
CY2012 lly Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 USD
CY2011 lly Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
388000000 USD
CY2010 lly Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
50000000 USD
CY2010 lly Acquired In Process Research And Development Net Of Tax
AcquiredInProcessResearchAndDevelopmentNetOfTax
32500000 USD
CY2012 lly Acquired In Process Research And Development Net Of Tax
AcquiredInProcessResearchAndDevelopmentNetOfTax
0 USD
CY2011 lly Acquired In Process Research And Development Net Of Tax
AcquiredInProcessResearchAndDevelopmentNetOfTax
252200000 USD
CY2012 lly Acquisitions Text Block New
AcquisitionsTextBlockNew
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#cc0000;font-weight:bold;">Note&#160;3:&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">From </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> to </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2012</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, we completed the acquisitions of ChemGen Corporation (ChemGen), the animal health business of Janssen Pharmaceuticia NV (Janssen), Avid Radiopharmaceuticals, Inc. (Avid), Alnara Pharmaceuticals, Inc. (Alnara), and a group of animal health product lines. These acquisitions were accounted for as business combinations under the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated financial statements from the date of acquisition. None of these acquisitions were material to our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">These acquisitions included IPR&amp;D, which represented compounds, new indications, or line extensions under development that had not yet achieved regulatory approval for marketing. As discussed in Note 1, the fair values of IPR&amp;D assets acquired as part of the acquisition of a business are capitalized as intangible assets. We capitalized </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$1.6 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$29.6 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$598.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of IPR&amp;D assets that were acquired in business combinations during the years ended </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2012</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2011</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, respectively. The ongoing expenses with respect to each of these assets in development are not material to our total research and development expense currently and are not expected to be material to our total research and development expense on an annual basis in the future.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">Some of these acquisitions included contingent consideration, which is recorded at fair value in other liabilities as of the acquisition date. The fair value of the contingent consideration was determined by utilizing a probability weighted estimated cash flow stream discounted for the expected timing of each payment. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">In addition to the acquisitions of businesses, we also acquired several assets in development during 2011 and 2010, which are discussed below in Product Acquisitions and in Note 4. The acquired IPR&amp;D related to these products of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$388.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$50.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2011</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2010</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, respectively, was written off by a charge to income immediately upon acquisition because the products had no alternative future use.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">In connection with the arrangements described below, our partners may be entitled to future milestones and royalties based on sales should these products be approved for commercialization.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;font-weight:bold;">Acquisition of Businesses</font></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><font style="font-family:Arial;font-size:9.75pt;font-style:italic;">ChemGen</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">On February&#160;17, 2012, we acquired all of the outstanding stock of ChemGen Corporation, a privately-held bioscience company specializing in the development and commercialization of innovative feed-enzyme products that improve the efficiency of poultry, egg, and meat production, for total purchase consideration of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$206.9 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> in cash. In connection with this acquisition, we preliminarily recorded </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$151.5 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of marketed product assets, with </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$55.4 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of other net assets. The final determination may result in asset and liability fair values that differ from the preliminary estimates, but it is not expected that these differences will be material to our consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><font style="font-family:Arial;font-size:9.75pt;font-style:italic;">Janssen</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">On July&#160;7, 2011, we acquired the animal health business of Janssen, a Johnson&#160;&amp; Johnson company, for total purchase consideration of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$307.8 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> in cash. We obtained a portfolio of more than </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> marketed animal health products. In connection with this acquisition, we recorded </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$234.4 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of marketed product assets and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$29.6 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of acquired IPR&amp;D assets, with </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$43.8 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of other net assets.</font></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><font style="font-family:Arial;font-size:9.75pt;font-style:italic;">Avid</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">On December&#160;20, 2010, we acquired all of the outstanding stock of Avid, a company focusing on developing molecular radiopharmaceutical tracers in positron emission tomography (PET) scan imaging, for total purchase consideration of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$346.1 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, which included an upfront payment of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$286.3 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> and up to </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$550&#160;million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> in additional payments contingent upon potential future regulatory and commercial milestones. The fair value of the contingent consideration at the acquisition date was </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$59.8 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">. In connection with this acquisition, we recorded </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$334.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of acquired IPR&amp;D assets, </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$119.6 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of goodwill, and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$116.9&#160;million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of deferred tax liability, with </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$9.4 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of other net assets. Avid&#8217;s lead product, Amyvid, is a PET agent indicated for imaging amyloid plaque pathology in the brain to aid the evaluation of patients with signs or symptoms of cognitive impairment. During the year ended December&#160;31, 2011, we recorded impairment charges for the IPR&amp;D asset related to Amyvid, as discussed further in Note 7. Amyvid received regulatory approval in the U.S. in 2012 and European Union in 2013, and is available to a limited number of imaging centers.</font></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><font style="font-family:Arial;font-size:9.75pt;font-style:italic;">Alnara</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">On July&#160;20, 2010, we acquired all of the outstanding stock of Alnara, a privately-held company developing protein therapeutics for the treatment of metabolic diseases, for total purchase consideration of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$291.7&#160;million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">, which included an upfront payment of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$188.7 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> and up to </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$200 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> in additional payments contingent upon potential future regulatory and commercial milestones. The fair value of the contingent consideration at the acquisition date was </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$103.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">. In connection with this acquisition, we recorded </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$264.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of acquired IPR&amp;D assets, </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$100.5 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of goodwill, and </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$92.4 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of deferred tax liability, with </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$19.6 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of other net assets. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy. The New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in the first quarter of 2010. In April 2011, we received a complete response letter that communicated the need for us to conduct an additional clinical trial prior to a resubmission. During the years ended December&#160;31, 2012 and 2011, we recorded impairment charges for the IPR&amp;D asset related to liprotamase, as discussed further in Note 7. </font></div><div style="line-height:120%;padding-top:12px;font-size:9.75pt;"><font style="font-family:Arial;font-size:9.75pt;font-style:italic;">Animal Health Product Lines</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">On May&#160;28, 2010, we acquired the European marketing rights to several animal health product lines divested by Pfizer Inc., for total purchase consideration of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$148.4 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> paid in cash. These products, including vaccines, parasiticides, and feed additives, serve both the production animal and companion animal markets. We also acquired a manufacturing facility in Sligo, Ireland, currently used in the production of animal vaccines. In connection with this acquisition, we recorded </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$76.2 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of marketed product intangible assets, with </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$72.2 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> of other net assets.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;font-weight:bold;">Product Acquisitions</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;font-size:10pt;"><font style="font-family:DIN Regular,sans-serif;font-size:10pt;">In March 2010, we entered into a license agreement with Acrux Limited to acquire the exclusive rights to commercialize its proprietary testosterone solution Axiron. At the time of the licensing, the product had not been approved and had no alternative future use. The charge of </font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">$50.0 million</font><font style="font-family:DIN Regular,sans-serif;font-size:10pt;"> for acquired IPR&amp;D related to this arrangement was included as expense in the first quarter of 2010 and is deductible for tax purposes. In the fourth quarter of 2010, Axiron was approved by the FDA for the treatment of testosterone deficiency in men. In the first quarter of 2011, the product was available in pharmacies in the United States.</font></div></div>
CY2012Q4 lly Available For Sale Securities Continuous Unrealized Gain Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedGainPositionFairValue
5246000000 USD
CY2011Q4 lly Available For Sale Securities Continuous Unrealized Gain Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedGainPositionFairValue
2498900000 USD
CY2011Q3 lly Business Acquisition Products Or Other Assets Acquired
BusinessAcquisitionProductsOrOtherAssetsAcquired
50
CY2010 lly Collaborative Arrangement Income Statement Classification And Amounts
CollaborativeArrangementIncomeStatementClassificationAndAmounts
174500000 USD
CY2012 lly Collaborative Arrangement Income Statement Classification And Amounts
CollaborativeArrangementIncomeStatementClassificationAndAmounts
261500000 USD
CY2011 lly Collaborative Arrangement Income Statement Classification And Amounts
CollaborativeArrangementIncomeStatementClassificationAndAmounts
219200000 USD
CY2012 lly Cost Of Sales Operating Expenses And Other Net
CostOfSalesOperatingExpensesAndOtherNet
17195200000 USD
CY2011 lly Cost Of Sales Operating Expenses And Other Net
CostOfSalesOperatingExpensesAndOtherNet
18937000000 USD
CY2010 lly Cost Of Sales Operating Expenses And Other Net
CostOfSalesOperatingExpensesAndOtherNet
16550800000 USD
CY2011Q4 lly Deferred Tax Assets Asset Purchases
DeferredTaxAssetsAssetPurchases
386200000 USD
CY2011Q4 lly Deferred Tax Assets Debt
DeferredTaxAssetsDebt
214900000 USD
CY2012 lly Defined Benefit Plan Direction And Pattern For Assumed Health Care Cost Trend Rate
DefinedBenefitPlanDirectionAndPatternForAssumedHealthCareCostTrendRate
0.003
CY2012 lly Defined Benefit Plan Percentage Of Global Investments In Plan Assets
DefinedBenefitPlanPercentageOfGlobalInvestmentsInPlanAssets
0.81
CY2012Q4 lly Defined Benefit Plan Plans With Projected Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets
DefinedBenefitPlanPlansWithProjectedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
6890000000 USD
CY2011Q4 lly Defined Benefit Plan Plans With Projected Benefit Obligations In Excess Of Plan Assets Aggregate Fair Value Of Plan Assets
DefinedBenefitPlanPlansWithProjectedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
5960000000 USD
CY2012Q4 lly Description Of Derivative Activity Volume Percent
DescriptionOfDerivativeActivityVolumePercent
0.60
CY2011 lly Domestic Contribution To Income Before Income Taxes
DomesticContributionToIncomeBeforeIncomeTaxes
0.24
CY2012 lly Domestic Contribution To Income Before Income Taxes
DomesticContributionToIncomeBeforeIncomeTaxes
0.54
CY2010 lly Domestic Contribution To Income Before Income Taxes
DomesticContributionToIncomeBeforeIncomeTaxes
0.45
CY2011Q4 lly Goodwill And Other Intangibles Net
GoodwillAndOtherIntangiblesNet
5128100000 USD
CY2012Q4 lly Goodwill And Other Intangibles Net
GoodwillAndOtherIntangiblesNet
4752700000 USD
CY2010Q1 lly Income Tax Expense Noncash Item Us Health Care Reform Act
IncomeTaxExpenseNoncashItemUsHealthCareReformAct
85100000 USD
CY2012 lly Income Tax Reconciliation Additions Us Health Care Reform Tax Law
IncomeTaxReconciliationAdditionsUsHealthCareReformTaxLaw
59800000 USD
CY2011 lly Income Tax Reconciliation Additions Us Health Care Reform Tax Law
IncomeTaxReconciliationAdditionsUsHealthCareReformTaxLaw
62900000 USD
CY2010 lly Income Tax Reconciliation Additions Us Health Care Reform Tax Law
IncomeTaxReconciliationAdditionsUsHealthCareReformTaxLaw
85100000 USD
CY2012Q4 lly Intangible Assets Gross
IntangibleAssetsGross
1566300000 USD
CY2011Q4 lly Intangible Assets Gross
IntangibleAssetsGross
1909600000 USD
CY2012Q4 lly Line Of Credit Facility Collateral Amount
LineOfCreditFacilityCollateralAmount
1200000000 USD
CY2011Q4 lly Long Term Debt Fair Value Adjustment
LongTermDebtFairValueAdjustment
556500000 USD
CY2012Q4 lly Long Term Debt Fair Value Adjustment
LongTermDebtFairValueAdjustment
606600000 USD
CY2012 lly Pension And Other Postretirement Benefit Contributions Discretionary
PensionAndOtherPostretirementBenefitContributionsDiscretionary
300000000 USD
CY2010 lly Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
50000000 USD
CY2012 lly Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
0 USD
CY2011 lly Purchased In Process Research And Development
PurchasedInProcessResearchAndDevelopment
388000000 USD
CY2012Q4 lly Sales Rebates And Discounts
SalesRebatesAndDiscounts
1777200000 USD
CY2011Q4 lly Sales Rebates And Discounts
SalesRebatesAndDiscounts
1771300000 USD
CY2013 lly Share Based Compensation Arrangement By Share Based Payment Award Expected Shares To Be Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedSharesToBeIssued
700000 shares
CY2012 lly Weighted Average Number Of Shares Outstanding Common Shares
WeightedAverageNumberOfSharesOutstandingCommonShares
1117294000 shares
CY2011 lly Weighted Average Number Of Shares Outstanding Common Shares
WeightedAverageNumberOfSharesOutstandingCommonShares
1113967000 shares
CY2010 lly Weighted Average Number Of Shares Outstanding Common Shares
WeightedAverageNumberOfSharesOutstandingCommonShares
1105813000 shares
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q4
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0000059478
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1134411762 shares
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2012Q2 dei Entity Public Float
EntityPublicFloat
42793000000 USD
CY2012 dei Entity Registrant Name
EntityRegistrantName
Lilly Eli & Co
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes

Files In Submission

Name View Source Status
0000059478-13-000007-index-headers.html Edgar Link pending
0000059478-13-000007-index.html Edgar Link pending
0000059478-13-000007.txt Edgar Link pending
0000059478-13-000007-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g266023g32y59.jpg Edgar Link pending
lly-20121221x10kexhibit21.htm Edgar Link pending
lly-20121231.xml Edgar Link completed
lly-20121231.xsd Edgar Link pending
lly-20121231x10k.htm Edgar Link pending
lly-20121231x10kexhibit1011.htm Edgar Link pending
lly-20121231x10kexhibit12.htm Edgar Link pending
lly-20121231x10kexhibit23.htm Edgar Link pending
lly-20121231x10kexhibit311.htm Edgar Link pending
lly-20121231x10kexhibit312.htm Edgar Link pending
lly-20121231x10kexhibit32.htm Edgar Link pending
lly-20121231_cal.xml Edgar Link unprocessable
lly-20121231_chart.jpg Edgar Link pending
lly-20121231_def.xml Edgar Link unprocessable
lly-20121231_lab.xml Edgar Link unprocessable
lly-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending